Loading clinical trials...
Loading clinical trials...
A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease
Conditions
Interventions
APL-130277
Locations
4
United States
Banner Sun Health Research Institute
Sun City, Arizona, United States
Rocky Mountain Movement Disorders Center
Englewood, Colorado, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
University of South Florida Parkinson's Disease and Movement Disorders Center
Tampa, Florida, United States
Start Date
August 31, 2014
Primary Completion Date
November 24, 2014
Completion Date
November 24, 2014
Last Updated
July 30, 2020
NCT07330258
NCT06508801
NCT07310264
NCT02119611
NCT07216976
NCT06402955
Lead Sponsor
Sumitomo Pharma America, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions